Dr. Anne Zeck

Research interests

Analytical chemistry with focus on chromatography and mass spectrometry of peptides and proteins

  • Detailed characterization of recombinant proteins and protein conjugates
  • Determination of identity / investigation of polyclonality
  • Determination of the coupling density of protein conjugates
  • High sensitivity sequence variant analysis
  • Determination of correct disulfide bridging
  • GlycosylationDetermination of N- and C-terminal modifications
  • Oxidation, deamidation, succinimide formation, glycation, etc.
  • Epitope mapping using H/D exchange and top down mass spectrometry
  • Immunoanalytical methods for the production and characterization of antibodies

Analytical Techniques

  • mass spectrometry
  • LTQ Orbitrap & LTQ-FT-ICR (ThermoScientific)
  • ESI-ToF and ESI-Q-ToF (MAXIS, Bruker)
  • chromatography
  • HPLC, (Ultimate 3000, Agilent 1100, nanoAcquity)
  • UPLC, RSLC (nanoAcquity, Ultimate 3000)
  • On-line enrichment
  • immunonalytics
  • ELISA, immunoprecipitation, immunaffinity enrichment
  • Immunoanalytical detection of chromatographic separations

other protein analytical techniques

  • ion scarf chromatography
  • SDS-PAGE, Western Blot


Curriculum vitae

2007 - 2011 Group leader, Roche Diagnostics GmbH, Penzberg

2006 - 2007 Postdoc at Roche Diagnostics GmbH, Penzberg

2004 Postdoc at Barnett Institute of Chemical and Biological Analysis Northeastern University, Boston, USA

2001 Dr. rer. nat. in Analytical Chemistry, Technical University Munich (TUM)

1992 - 1998 Chemistry studies and Dipl. Chem. at the TU Karlsruhe and TUM


Dr. Anne Zeck
Group Leader Bioanalytics
T +49 (0)7121 51530-811
F +49 (0)7121 51530-62


  • Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity
    Becker M, Strengert M, Junker D, Kaiser P, Kerrinnes T, Traenkle B, Dinter H, Häring J, Ghozzi S, Zeck A, Weise F, Peter A, Hörber S, Fink S, Ruoff F, Dulovic A, Bakchoul T, Baillot A, Lohse S, Cornberg M, Illig T, Gottlieb J, Smola S, Karch A, Berger K, Rammensee HG, Schenke-Layland K, Nelde A, Märklin M, Heitmann JS, Walz JS, Templin M, Joos TO, Rothbauer U, Krause K & Schneiderhan-Marra N
    NATURE COMMUNICATIONS | (2021) 12:1152 | https://doi.org/10.1038/s41467-021-20973-3 | www.nature.com/naturecommunications
  • Impact of S-sulfocysteine on fragments and trisulfide bond linkages in monoclonal antibodies
    Seibel R, Maier S, Schnellbaecher A, Bohl S, Wehsling M, Zeck A, Zimmer A
    MAbs. 2017 Aug/Sep;9(6):889-897. doi: 10.1080/19420862.2017.1333212. Epub 2017 Jun 5.
  • Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols
    Loffler MW, Schuster H, Zeck A, Quilitz N, Weinreich J, Tolios A, Haen SP, Horvath P, Lob S, Rammensee HG, Konigsrainer I, Konigsrainer A, Beckert S
    Ann Surg Oncol. 2017 Jun;24(6):1650-1657. doi: 10.1245/s10434-017-5790-x. Epub 2017 Feb 3.
  • MASP-1 and MASP-2 Do Not Activate Pro-Factor D in Resting Human Blood, whereas MASP-3 Is a Potential Activator: Kinetic Analysis Involving Specific MASP-1 and MASP-2 Inhibitors
    Oroszlan G, Kortvely E, Szakacs D, Kocsis A, Dammeier S, Zeck A, Ueffing M, Zavodszky P, Pal G, Gal P, Dobo J
    J Immunol. 2016 Jan 15;196(2):857-65. doi: 10.4049/jimmunol.1501717. Epub 2015 Dec 16.
  • Determination of antibody glycosylation by mass spectrometry
    Jager C, Ferrara C, Umana P, Zeck A, Regula JT, Koll H
    Methods Mol Biol. 2012;901:195-208. doi: 10.1007/978-1-61779-931-0_13.
  • Low level sequence variant analysis of recombinant proteins: an optimized approach
    Zeck A, Regula JT, Larraillet V, Mautz B, Popp O, Gopfert U, Wiegeshoff F, Vollertsen UE, Gorr IH, Koll H, Papadimitriou A
    PLoS One. 2012;7(7):e40328. Epub 2012 Jul 6.
  • Cell Type-Specific and Site Directed N-Glycosylation Pattern of FcgammaRIIIa
    Zeck A, Pohlentz G, Schlothauer T, Peter-Katalinic J, Regula JT
    J. Proteome Res. 2011;10(7):3031–3039. DOI: 10.1021/pr1012653